Company profile
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was
- CEO
- Mr. Richard Jon Barry
- Headquarters
- Austin, TX, United States
- Employees
- 30
- IPO date
- Jul 14, 2000
- Sector
- Healthcare
- Industry
- Biotechnology